The United States of America, As Represented by the Secretary, Department of Health and Human Services

Scitech Development, LLC

Wayne State University

Jasti, Bhaskara R.

Ralph E Parchment

Thomas D Pfister

Robert J Kinders

Tony Navas

James Halpern Doroshow

Bhaskara Rao Jasti

Earle T Holsapple

Apurva K Srivastava

James E Doroshow

Allison M Marrero

Ramesh R Boinpally

Stephen E Rose

Bhaskara R Jasti

Steven E Rose

Methods and compositions are described herein for assaying the presence or absence of pY1235-MET or a fragment thereof.

Anti-pY1235-MET immunological binding reagent

Monoclonal antibodies that specifically bind ataxia telangiectasia-mutated and RAD3-related kinase phosphorylated at position 1989 (pT1989 ATR), antigen binding fragments, conjugates thereof, and the use of these antibodies, antigen binding fragments and conjugates are disclosed herein. Also disclosed are nucleic acids encoding these antibodies, vectors including these antibodies, and isolated host cells transformed with these nucleic acids and vectors. Methods are also disclosed for using these antibodies, such as to detect pT1989 ATR, or to determine the dose of an agent of use to treat a subject. The antibodies are also of use for identifying ATR inhibitors.

Antibodies that specifically bind ataxia telangiectasia-mutated and RAD3-related kinase phosphorylated at position 1989 and their use

Formulations of neutral retinoids, in particular fenretinide (HPR) in the form of lipid nanoparticles, solid dispersions and emulsions are disclosed. These compositions are used to treat diseases that are amenable to treatment by HPR, such as neoplastic diseases by achieving higher and more prolonged concentrations of HPR in the subject. The key steps for preparing lipid nanovesicles of HPR include mixing and sonication, sterile filtration, without or without lyophilization for long-term stable storage, and employ processes and materials that are scalable from the laboratory to the manufacturing level. The formulation are suitable for injection into human or animal patients without causing allergic or hypersensitivity responses by avoiding chemical surfactants and animal sources of phospholipids in their manufacture.

Liposomal nanoparticles and other formulations of fenretinide for use in therapy and drug delivery

Growing community of inventors

Hagerstown, MD, United States of America

Ralph E Parchment